| Features: nonsteroidal anti-inflammatory drug (NSAID) |
| Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory. -Aspirin irreversibly inhibits the enzyme cyclooxygenase-1 (COX-1). This inhibition reduces the production of thromboxane A₂, a potent promoter of platelet aggregation. -low-dose aspirin is frequently used for the prevention of cardiovascular events such as heart attacks and strokes in individuals at risk. |
| 1028- | ASA, | Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development |
| - | vitro+vivo, | Ovarian, | NA |
| 1096- | ASA, | Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review) |
| - | Review, | NA, | NA |
| 1304- | ASA, | Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells |
| - | in-vitro, | CRC, | NA | - | in-vivo, | NA, | NA |
| 2461- | ASA, | Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis |
| - | Review, | NA, | NA |
| 2561- | EGCG, | ASA, | Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment |
| - | ex-vivo, | Nor, | NA |
| 1218- | VitC, | ASA, | Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production |
| - | in-vitro, | GBM, | SK-N-SH |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:1 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid